CORCEPT THERAPEUTICS INC

CORT, which trades under the ticker CORT, is the common stock of Corcept Therapeutics, a biopharmaceutical company focused on developing and commercializing drugs that modulate the hormone cortisol. The company's primary commercial product is Korlym (mifepristone), used to treat Cushing's syndrome, a condition caused by excessive cortisol. Corcept is also researching additional cortisol modulators for oncology and metabolic disorders. For a comprehensive overview of its operations, refer to the company description on the CORT stock page.

The ticker CORT represents a company operating in the biotechnology and pharmaceutical industry. Specifically, Corcept Therapeutics is a commercial-stage biopharmaceutical firm that discovers, develops, and markets medications targeting cortisol modulation. This sector is characterized by rigorous regulatory oversight, lengthy drug development timelines, and significant research and development expenditures. For a more detailed industry classification, please see the CORT stock page.

Recent performance of CORT can be influenced by drug trial results, regulatory decisions, and financial reports. Since current price and performance data fluctuate, the most accurate and up-to-date information is available on the CORT stock page, which displays the latest price, percentage change, and other key metrics. For a comprehensive view of recent performance, including charts and historical data, please refer to the CORT stock page.

The 52-week range for CORT shows the lowest and highest prices at which the stock has traded over the past year. This range can help investors understand the stock's volatility and price extremes. For the current 52-week range, please check the CORT stock page, as this data updates regularly and should be verified with the latest information available there.

Investing in CORT involves significant risks typical of biopharmaceutical companies. Key risks include clinical trial failures, regulatory delays or rejections, competition from other treatments, and reliance on a limited number of products. Additionally, CORT's financial performance can be affected by changes in reimbursement policies, patent expirations, and the ability to obtain adequate financing for research. For a comprehensive list of risks, investors should review the company's SEC filings and the CORT stock page.

When researching CORT, important financial metrics include revenue growth, net income, earnings per share (EPS), and operating cash flow. These indicators provide insight into the company's profitability, financial health, and growth trajectory. Additionally, research and development expenses are crucial for biopharmaceutical firms, as they reflect investment in future product pipelines. For current figures, refer to the CORT stock page or the company's financial statements.